2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders

      research-article

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Proton pump inhibitors (PPIs) have been in use since the early 1990s and play a crucial role in the management of a number of conditions affecting the upper gastrointestinal tract, including gastroesophageal reflux disease, Barrett esophagus, eosinophilic esophagitis, and dyspepsia. PPIs also play an important role in the treatment of Helicobacter pylori infection and in the prevention of upper gastrointestinal tract ulcers and bleeding among patients taking antiplatelet therapy and/or nonsteroidal anti-inflammatory drugs. Despite recent concerns regarding the long-term safety of PPIs, their risk-benefit profiles strongly favor their appropriate use in patients who have genuine indications for them. As with all drugs, PPIs should be administered in the lowest effective dose and only for as long as clinically indicated. However, for at least some of their approved indications, PPIs are likely to be required indefinitely. This article outlines the current indications for PPIs for the management of upper gastrointestinal disorders and reviews safety concerns.

          Related collections

          Author and article information

          Journal
          Gastroenterol Hepatol (N Y)
          Gastroenterol Hepatol (N Y)
          GH
          Gastroenterology & Hepatology
          Millennium Medical Publishing
          1554-7914
          March 2018
          : 14
          : 3
          : 169-175
          Affiliations
          Dr Khan is a third year gastroenterology fellow and Dr Howden is the Hyman Professor of Medicine and Chief of the Division of Gastroenterology at the University of Tennessee Health Science Center in Memphis, Tennessee.
          Author notes
          Address correspondence to: Dr Colin W. Howden 956 Court Avenue, Suite H210 Memphis, TN 38163 Tel: 901-448-2117 Fax: 901-448-7091 E-mail: chowden@ 123456uthsc.edu

          Dr Howden has been a consultant, investigator, and/or speaker for all proton pump inhibitor manufacturers at one time. He is currently a consultant for Pfizer Consumer Healthcare, Aralez Pharmaceuticals, Ironwood Pharmaceuticals, US WorldMeds, and SynteractHCR. Dr Khan has no relevant conflicts of interest to disclose.

          Article
          PMC6004044 PMC6004044 6004044 GH_14_169
          6004044
          29928161
          8f74d235-1886-44ef-907f-ef24f95d5399
          Copyright © 2018, Gastro-Hep Communications, Inc.
          History
          Categories
          Column

          eosinophilic esophagitis,nonsteroidal anti-inflammatory drugs,peptic ulcer disease, Helicobacter pylori infection,gastroesophageal reflux disease,Proton pump inhibitors

          Comments

          Comment on this article